Letter to the editor: Hepatitis B virus reactivation in immune checkpoint inhibitor-based combination therapies for hepatocellular carcinoma.

Abstract

To the editor, We read with great interest the article by Papatheodoridi et al.1 that systematically reviewed data on hepatitis B virus (HBV) reactivation in patients who were Hepatitis B surface antigen (HBsAg) positive with hepatocellular carcinoma (HCC) receiving different therapy. Prophylactic antiviral treatment should be performed regardless of HCC treatment. However, there are a few reservations that are worth further in‐depth discussion. The risk and exact mechahnism of HBV reactivation induced by immune checkpoint inhibitors (ICIs) in HCC remain unclear and are still a matter of discussion. The programmed death‐1/programmed death‐ligand 1 (PD‐1/PD‐L1) axis plays an important role not only in cancer immune evasion but also in hepatitis virus infection. Blocking PD‐1/PD‐L1 axis can partially restore the defective HBV‐specific T and B cell responses. A pilot study found that nivolumab correlates with HBsAg levels declining in patients with chronic hepatitis B.2 Nevertheless, in the Asian cohort of the CheckMate 040 trial of nivolumab in adults with advanced HCC, 11% (5/47) of patients with HBV had >1 log increase in HBV DNA.3 This paradoxical effect might be explained by ICI treatment disrupting immune homeostasis, resulting in viral reactivation rather than expected viral suppression. Six studies included 366 patients treated with systemic therapy and provided reactivation data in this review. First, there was one data extraction error. Among them, one study (reference 51) published by Lee et al. included patients with HCC treated with ICIs with or without tyrosine kinase inhibitors rather than sorafenib.4 Lee et al. found only one patient who had not received antiviral therapy had HBV reactivation and no patients on antiviral therapy developed reactivation. However, there were three patients with serum HBV DNA that was undetectable to detectable but less than 1000 IU/ml during ICI treatment. This has a slight effect on the pooled reactivation rate. In addition, most patients in the systemic therapy group received different combination regimens with different mechanisms of action, including sorafenib plus transarterial chemoembolization, and ICIs with or without antiangiogenetic agents. The pooled incidence rate might not be comprehensive or accurate by mixing those studies. We agree that limited data on HBV reactivation risk in patients with HCC who receive systemic therapy were insufficient for subgroup analysis by specific regimen. This discrepancy highlights the need for cautious interpretation of the reactivation results for systemic therapy, particularly in ICI‐based therapy.